Prof. Danijel Kikelj

Danijel Kikelj is Professor of medicinal chemistry at the Faculty of Pharmacy, University of Ljubljana, Slovenia. He graduated in pharmacy at the University of Ljubljana  and obtained his doctoral degree in pharmaceutical chemistry at the University of Heidelberg, Germany, in 1988. His scientific interest includes design and synthesis of peptidomimetics, structure based design of antithrombotic and antibacterial compounds, designed multiple ligands, and design and synthesis of pharmaceutical leads based on marine bioactive compounds. He has authored over 100 papers in international journals, several international patents and three monographs in the series Houben-Weyl Methods of organic chemistry and Science of synthesis: Houben-Weyl methods of molecular transformations. Danijel Kikelj is member of editorial boards of the journals Current Medicinal Chemistry, Acta Chimica Slovenica, Acta Pharmaceutica, Arkivoc and Chemical Biology and Drug Design.

Prof. Kikelj is Workpackage Leader for WP2, with the aim of coordinating and exploiting the medicinal and synthetic organic chemistry activities directed to the design and synthesis of low molecular weight compounds to be evaluated as potential Gram-negative antibacterial agents. Prof. Kikelj also serves as the main supervisor for ESR7. The research project of ESR7 involves design, synthesis and evaluation of structurally novel gyrase B inhibitors and gyrase B/topoisomerase IV (ParE) dual inhibitors and achieving their in vitro antibacterial activity by modifications which will improve entry of inhibitors into bacteria (WP2).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement No  642620
European Union